Lipid Nanoparticles Market By Type , By Application By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033

Description

The global lipid nanoparticles market was valued at $0.9 billion in 2023, and is projected to reach $3.1 billion by 2033, growing at a CAGR of 13.1% from 2024 to 2033

Lipid nanoparticles (LNPs) are nanoscale particles ranging from 10 to 1000 nanometers in diameter, primarily composed of lipids. They are designed to encapsulate therapeutic agents such as drugs, vaccines, and genetic materials, protecting them from degradation and enhancing their delivery and efficacy. LNPs can mimic the structure of biological membranes, making them biocompatible and capable of efficiently interacting with and penetrating cells. Their lipid composition typically includes phospholipids, cholesterol, and other lipid molecules that aid in stabilizing the nanoparticle structure and controlling the release of the encapsulated cargo.

The growth of the lipid nanoparticles market is driven by rise in the prevalence of chronic diseases, such as cancer, diabetes, cardiovascular diseases, and neurological disorders, and surge in demand for advanced drug delivery systems. These conditions often require long-term treatment with drugs that have severe side effects when administered through traditional methods. LNPs offer a promising alternative by enabling targeted and sustained delivery of therapeutic agents, thereby reducing systemic side effects and improving patient compliance. In oncology, for instance, LNPs are used to deliver chemotherapeutic agents directly to tumor cells, minimizing damage to healthy tissues.

However, high cost associated with the production and development of LNP-based formulations, as the manufacturing process involves sophisticated technology and stringent quality control measures to ensure the stability and efficacy of the nanoparticles, leads to increased production costs which limit the market growth. On the contrary, advances in nanotechnology facilitated the development of lipid nanoparticles with enhanced stability, targeted delivery, and controlled release properties. This opened new avenues for drug delivery, allowing for more effective and efficient therapeutic interventions. For instance, in January 2022, Pfizer Inc. and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA) -based therapeutics announced that they had entered into a development and option agreement under which Pfizer will have the option to license, on a non-exclusive basis, Acuitas' LNP technology for up to 10 targets for vaccine or therapeutic development.

Segmentation Overview

The lipid nanoparticles market analysis is segmented into type, application, end user, and region. Depending on type, the market is categorized into solid lipid nanoparticles, nanostructured lipid carriers, and others. By application, it is bifurcated into therapeutics and research. As per end user, the market is classified into pharmaceutical & biotechnology companies, academic & research institutes, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the solid lipid nanoparticles segment held the highest market share in 2023.

Depending on the application, the therapeutics segment accounted for maximum share in the market in 2023.

According to end user, the pharmaceutical & biotechnology companies have been the largest shareholder in the market in 2023.

Region wise, North America dominated the lipid nanoparticles market in 2023.

Competitive Scenario

The major players operating in the lipid nanoparticles market include ABP Biosciences, LLC., Merck KGaA, Cytiva, CD Bioparticles, CordenPharma, Precigenome LLC., Beam Therapeutics, Acuitas Therapeutics, GENEVANT SCIENCES CORPORATION, and Helix Biotech, Inc. Other players in lipid nanoparticles market includes Arbutus Biopharma, and Croda International Plc. These players have adopted several strategies, including mergers & acquisitions, collaborations, product innovation & diversification, and partnerships, to maintain their foothold in the market.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

Solid Lipid Nanoparticles
Nanostructured Lipid Carriers
Others

By Application

Therapeutics
Research

By End User

Pharmaceutical and Biotechnology Companies
Academic and Research Institutes
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

ABP Biosciences, LLC.
Merck KGaA
Cytiva
CD Bioparticles
CordenPharma
Precigenome LLC.
Beam Therapeutics
Acuitas Therapeutics.
Helix Biotech, Inc.
Genevant Sciences Corporation

Product Code: A323703

CHAPTER 1: INTRODUCTION

1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope
3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities

CHAPTER 4: LIPID NANOPARTICLES MARKET, BY TYPE

4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Type
4.2. Solid Lipid Nanoparticles
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
4.3. Nanostructured Lipid Carriers
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
4.4. Others
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country

CHAPTER 5: LIPID NANOPARTICLES MARKET, BY APPLICATION

5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Application
5.2. Therapeutics
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
5.3. Research
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country

CHAPTER 6: LIPID NANOPARTICLES MARKET, BY END USER

6.1. Market Overview
- 6.1.1 Market Size and Forecast, By End User
6.2. Pharmaceutical And Biotechnology Companies
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
6.3. Academic And Research Institutes
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
6.4. Others
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country

CHAPTER 7: LIPID NANOPARTICLES MARKET, BY REGION

7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Type
- 7.2.3. Market Size and Forecast, By Application
- 7.2.4. Market Size and Forecast, By End User
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Lipid Nanoparticles Market
  - 7.2.6.1. Market Size and Forecast, By Type
  - 7.2.6.2. Market Size and Forecast, By Application
  - 7.2.6.3. Market Size and Forecast, By End User
- 7.2.7. Canada Lipid Nanoparticles Market
  - 7.2.7.1. Market Size and Forecast, By Type
  - 7.2.7.2. Market Size and Forecast, By Application
  - 7.2.7.3. Market Size and Forecast, By End User
- 7.2.8. Mexico Lipid Nanoparticles Market
  - 7.2.8.1. Market Size and Forecast, By Type
  - 7.2.8.2. Market Size and Forecast, By Application
  - 7.2.8.3. Market Size and Forecast, By End User
7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Type
- 7.3.3. Market Size and Forecast, By Application
- 7.3.4. Market Size and Forecast, By End User
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. Germany Lipid Nanoparticles Market
  - 7.3.6.1. Market Size and Forecast, By Type
  - 7.3.6.2. Market Size and Forecast, By Application
  - 7.3.6.3. Market Size and Forecast, By End User
- 7.3.7. France Lipid Nanoparticles Market
  - 7.3.7.1. Market Size and Forecast, By Type
  - 7.3.7.2. Market Size and Forecast, By Application
  - 7.3.7.3. Market Size and Forecast, By End User
- 7.3.8. UK Lipid Nanoparticles Market
  - 7.3.8.1. Market Size and Forecast, By Type
  - 7.3.8.2. Market Size and Forecast, By Application
  - 7.3.8.3. Market Size and Forecast, By End User
- 7.3.9. Italy Lipid Nanoparticles Market
  - 7.3.9.1. Market Size and Forecast, By Type
  - 7.3.9.2. Market Size and Forecast, By Application
  - 7.3.9.3. Market Size and Forecast, By End User
- 7.3.10. Spain Lipid Nanoparticles Market
  - 7.3.10.1. Market Size and Forecast, By Type
  - 7.3.10.2. Market Size and Forecast, By Application
  - 7.3.10.3. Market Size and Forecast, By End User
- 7.3.11. Rest of Europe Lipid Nanoparticles Market
  - 7.3.11.1. Market Size and Forecast, By Type
  - 7.3.11.2. Market Size and Forecast, By Application
  - 7.3.11.3. Market Size and Forecast, By End User
7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Type
- 7.4.3. Market Size and Forecast, By Application
- 7.4.4. Market Size and Forecast, By End User
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. Japan Lipid Nanoparticles Market
  - 7.4.6.1. Market Size and Forecast, By Type
  - 7.4.6.2. Market Size and Forecast, By Application
  - 7.4.6.3. Market Size and Forecast, By End User
- 7.4.7. China Lipid Nanoparticles Market
  - 7.4.7.1. Market Size and Forecast, By Type
  - 7.4.7.2. Market Size and Forecast, By Application
  - 7.4.7.3. Market Size and Forecast, By End User
- 7.4.8. India Lipid Nanoparticles Market
  - 7.4.8.1. Market Size and Forecast, By Type
  - 7.4.8.2. Market Size and Forecast, By Application
  - 7.4.8.3. Market Size and Forecast, By End User
- 7.4.9. Australia Lipid Nanoparticles Market
  - 7.4.9.1. Market Size and Forecast, By Type
  - 7.4.9.2. Market Size and Forecast, By Application
  - 7.4.9.3. Market Size and Forecast, By End User
- 7.4.10. South Korea Lipid Nanoparticles Market
  - 7.4.10.1. Market Size and Forecast, By Type
  - 7.4.10.2. Market Size and Forecast, By Application
  - 7.4.10.3. Market Size and Forecast, By End User
- 7.4.11. Rest of Asia-Pacific Lipid Nanoparticles Market
  - 7.4.11.1. Market Size and Forecast, By Type
  - 7.4.11.2. Market Size and Forecast, By Application
  - 7.4.11.3. Market Size and Forecast, By End User
7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Type
- 7.5.3. Market Size and Forecast, By Application
- 7.5.4. Market Size and Forecast, By End User
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Lipid Nanoparticles Market
  - 7.5.6.1. Market Size and Forecast, By Type
  - 7.5.6.2. Market Size and Forecast, By Application
  - 7.5.6.3. Market Size and Forecast, By End User
- 7.5.7. Saudi Arabia Lipid Nanoparticles Market
  - 7.5.7.1. Market Size and Forecast, By Type
  - 7.5.7.2. Market Size and Forecast, By Application
  - 7.5.7.3. Market Size and Forecast, By End User
- 7.5.8. South Africa Lipid Nanoparticles Market
  - 7.5.8.1. Market Size and Forecast, By Type
  - 7.5.8.2. Market Size and Forecast, By Application
  - 7.5.8.3. Market Size and Forecast, By End User
- 7.5.9. Rest of LAMEA Lipid Nanoparticles Market
  - 7.5.9.1. Market Size and Forecast, By Type
  - 7.5.9.2. Market Size and Forecast, By Application
  - 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

9.1. ABP Biosciences, LLC.
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
9.2. Merck KGaA
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
9.3. Cytiva
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
9.4. CD Bioparticles
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
9.5. CordenPharma
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
9.6. Precigenome LLC.
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
9.7. Beam Therapeutics
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
9.8. Acuitas Therapeutics.
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
9.9. Helix Biotech, Inc.
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
9.10. Genevant Sciences Corporation
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments